Compare CLLS & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLLS | PROF |
|---|---|---|
| Founded | 1999 | N/A |
| Country | France | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.0M | 248.8M |
| IPO Year | 2014 | 2017 |
| Metric | CLLS | PROF |
|---|---|---|
| Price | $1.04 | $7.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $5.50 | ★ $11.14 |
| AVG Volume (30 Days) | 84.3K | ★ 178.8K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $61.76 |
| Revenue Next Year | N/A | $70.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $0.88 | $4.91 |
| 52 Week High | $5.45 | $8.95 |
| Indicator | CLLS | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 54.23 |
| Support Level | $0.94 | $6.38 |
| Resistance Level | $1.28 | $7.19 |
| Average True Range (ATR) | 0.11 | 0.52 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 0.53 | 54.81 |
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.